先天性肾上腺增生症中改良释放型与常规糖皮质激素对昼间雄激素排泄的影响
该研究采用气相色谱-质谱法对55例先天性肾上腺增生症(CAH)成人和60名对照者进行24小时尿液类固醇代谢组分析,比较常规糖皮质激素与改良释放型氢化可的松(Chronocort)对经典及替代途径雄激素合成的影响。结果显示CAH患者常规糖皮质激素治疗下经典途径雄激素代谢物排泄低,但替代途径标志代谢物排泄过多;Chronocort较其他糖皮质激素制剂更持续地将17OHP及替代途径代谢物排泄降至接近正常水平。
要点
- CAH患者常规糖皮质激素治疗下替代途径标志代谢物3α,5α-17-羟基孕烷醇酮和11β-羟基雄酮排泄过多。
- Chronocort较其他糖皮质激素制剂更持续地将17OHP和替代途径代谢物排泄降至接近正常水平。
- 替代途径介导的雄激素合成显著促进CAH雄激素过多。
核心结论
- 替代途径介导的雄激素合成显著促进CAH雄激素过多。
- Chronocort治疗在通过减弱其主要底物17OHP来控制替代途径雄激素合成方面似乎优于常规糖皮质激素治疗。
研究设计与样本
- 采用气相色谱-质谱法进行24小时尿液类固醇代谢组分析,研究常规糖皮质激素(氢化可的松、泼尼松龙和地塞米松)对55例CAH成人和60名对照者的影响。
- 通过比较16例接受常规糖皮质激素的CAH患者在23:00-7:00、7:00-15:00和15:00-23:00的8小时尿液收集,以及在改良释放型氢化可的松Chronocort治疗6个月期间的收集,研究类固醇排泄的昼夜变化。
主要发现
- 接受常规糖皮质激素的CAH患者经典途径雄激素代谢物排泄低,但替代途径标志代谢物3α,5α-17-羟基孕烷醇酮和11β-羟基雄酮排泄过多。
- Chronocort较其他糖皮质激素制剂更持续地将17OHP和替代途径代谢物排泄降至接近正常水平。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The classic androgen synthesis pathway proceeds via dehydroepiandrosterone, androstenedione, and testosterone to 5α-dihydrotestosterone. However, 5α-dihydrotestosterone synthesis can also be achieved by an alternative pathway originating from 17α-hydroxyprogesterone (17OHP), which accumulates in congenital adrenal hyperplasia (CAH). Similarly, recent work has highlighted androstenedione-derived 11-oxygenated 19-carbon steroids as active androgens, and in CAH, androstenedione is generated directly from 17OHP. The exact contribution of alternative pathway activity to androgen excess in CAH and its response to glucocorticoid (GC) therapy is unknown. OBJECTIVE: We sought to quantify classic and alternative pathway-mediated androgen synthesis in CAH, their diurnal variation, and their response to conventional GC therapy and modified-release hydrocortisone. METHODS: We used urinary steroid metabolome profiling by gas chromatography-mass spectrometry for 24-hour steroid excretion analysis, studying the impact of conventional GCs (hydrocortisone, prednisolone, and dexamethasone) in 55 adults with CAH and 60 controls. We studied diurnal variation in steroid excretion by comparing 8-hourly collections (23:00-7:00, 7:00-15:00, and 15:00-23:00) in 16 patients with CAH taking conventional GCs and during 6 months of treatment with modified-release hydrocortisone, Chronocort. RESULTS: Patients with CAH taking conventional GCs showed low excretion of classic pathway androgen metabolites but excess excretion of the alternative pathway signature metabolites 3α,5α-17-hydroxypregnanolone and 11β-hydroxyandrosterone. Chronocort reduced 17OHP and alternative pathway metabolite excretion to near-normal levels more consistently than other GC preparations. CONCLUSIONS: Alternative pathway-mediated androgen synthesis significantly contributes to androgen excess in CAH. Chronocort therapy appears superior to conventional GC therapy in controlling androgen synthesis via alternative pathways through attenuation of their major substrate, 17OHP.
引用
- Jones CM, Mallappa A, Reisch N, et al. Modified-Release and Conventional Glucocorticoids and Diurnal Androgen Excretion in Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab. 2017. PMID: 27845856. doi:10.1210/jc.2016-2855
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。